{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:40:07Z","timestamp":1775274007055,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671631"],"award-info":[{"award-number":["81671631"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuroimmunology is a rapidly expanding field, and there have been recent discoveries of new antibodies and neurological syndromes. Most of the current clinical studies have focused on disorders involving one specific antibody. We have summarized a class of antibodies that target common neuronal epitopes, and we have proposed the term \u201canti-neuron antibody syndrome\u201d (ANAS). In this study, we aimed to clarify the clinical range and analyse the clinical features, cytokines\/chemokines and predictors in ANAS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort study investigating patients with neurological manifestations that were positive for anti-neuron antibodies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 110 patients were identified, of which 43 patients were classified as having autoimmune encephalitis (AE) and the other 67 were classified as having paraneoplastic neurological syndrome (PNS). With regards to anti-neuron antibodies, 42 patients tested positive for anti-N-methyl-D-aspartate receptor (NMDAR) antibody, 19 for anti-Hu, 14 for anti-Yo and 12 for anti-PNMA2 (Ma2). There were significant differences between the ANAS and control groups in serum B cell-activating factor (BAFF) levels and in cerebrospinal fluid (CSF) C-X-C motif chemokine10 (CXCL10), CXCL13, interleukin10 (IL10), BAFF and transforming growth factor \u03b21 (TGF\u03b21) levels. Predictors of poor outcomes included having tumours (<jats:italic>P<\/jats:italic> = 0.0193) and having a chronic onset (<jats:italic>P<\/jats:italic> = 0.0306), and predictors of relapses included having lower levels of CSF BAFF (<jats:italic>P<\/jats:italic> = 0.0491) and having a larger ratio of serum TGF\u03b21\/serum CXCL13 (<jats:italic>P<\/jats:italic> = 0.0182).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Most patients with ANAS had a relatively good prognosis. Having tumours and a chronic onset were both associated with poor outcomes. CSF BAFF and the ratio of serum TGF\u03b21\/serum CXCL13 were associated with relapses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-021-02259-z","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:05:59Z","timestamp":1638788759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-neuron antibody syndrome: clinical features, cytokines\/chemokines and predictors"],"prefix":"10.1186","volume":"18","author":[{"given":"Shaohua","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanfen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaiqiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-9485","authenticated-orcid":false,"given":"Bingzhen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"2259_CR1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1212\/WNL.0000000000003796","volume":"88","author":"M Hara","year":"2017","unstructured":"Hara M, Arino H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, et al. DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology. 2017;88:1340\u20138.","journal-title":"Neurology"},{"key":"2259_CR2","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/brain\/aws256","volume":"135","author":"RC Dale","year":"2012","unstructured":"Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135:3453\u201368.","journal-title":"Brain"},{"key":"2259_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"Gaig C, Graus F, Compta Y, Hogl B, Bataller L, Bruggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736\u201343.","journal-title":"Neurology"},{"key":"2259_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","volume":"8","author":"E Lancaster","year":"2012","unstructured":"Lancaster E, Dalmau J. Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8:380\u201390.","journal-title":"Nat Rev Neurol"},{"key":"2259_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25\u201336.","journal-title":"Ann Neurol"},{"key":"2259_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","volume":"9","author":"E Lancaster","year":"2010","unstructured":"Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67\u201376.","journal-title":"Lancet Neurol"},{"key":"2259_CR7","doi-asserted-by":"crossref","unstructured":"Sanjabi S, Oh SA, Li MO. Regulation of the Immune Response by TGF-beta: From Conception to Autoimmunity and Infection. Cold Spring Harb Perspect Biol. 2017;9(6):a022236.","DOI":"10.1101\/cshperspect.a022236"},{"key":"2259_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, O'Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50:871\u201391.","journal-title":"Immunity"},{"key":"2259_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1742-2094-9-93","volume":"9","author":"MC Kowarik","year":"2012","unstructured":"Kowarik MC, Cepok S, Sellner J, Grummel V, Weber MS, Korn T, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9:93.","journal-title":"J Neuroinflammation"},{"key":"2259_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ana.24494","volume":"78","author":"WK Roberts","year":"2015","unstructured":"Roberts WK, Blach\u00e8re NE, Frank MO, Dousmanis A, Ransohoff RM, Darnell RB. A destructive feedback loop mediated by CXCL 10 in central nervous system inflammatory disease. Ann Neurol. 2015;78:619\u201329.","journal-title":"Ann Neurol"},{"key":"2259_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cei.13039","volume":"190","author":"G Ferraccioli","year":"2017","unstructured":"Ferraccioli G, Gremese E. B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol. 2017;190:291\u20132.","journal-title":"Clin Exp Immunol"},{"key":"2259_CR12","doi-asserted-by":"publisher","first-page":"e0161656","DOI":"10.1371\/journal.pone.0161656","volume":"11","author":"K Kothur","year":"2016","unstructured":"Kothur K, Wienholt L, Mohammad SS, Tantsis EM, Pillai S, Britton PN, et al. Utility of CSF Cytokine\/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis. PLoS One. 2016;11:e0161656.","journal-title":"PLoS One"},{"key":"2259_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fneur.2018.00904","volume":"9","author":"YW Ding","year":"2018","unstructured":"Ding YW, Pan SY, Xie W, Shen HY, Wang HH. Elevated Soluble Fas and FasL in Cerebrospinal Fluid and Serum of Patients With Anti-N-methyl-D-aspartate Receptor Encephalitis. Front Neurol. 2018;9:904.","journal-title":"Front Neurol"},{"key":"2259_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/j.semdp.2019.06.005","volume":"36","author":"R Iorio","year":"2019","unstructured":"Iorio R, Spagni G, Masi G. Paraneoplastic neurological syndromes. Sem Diagn Pathol. 2019;36:279\u201392.","journal-title":"Sem Diagn Pathol"},{"key":"2259_CR15","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1212\/WNL.0000000000002775","volume":"86","author":"N Gresa-Arribas","year":"2016","unstructured":"Gresa-Arribas N, Planaguma J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, et al. Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86:2235\u201342.","journal-title":"Neurology"},{"key":"2259_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391\u2013404.","journal-title":"Lancet Neurol"},{"key":"2259_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4997\/JRCPE.2019.407","volume":"49","author":"JA Goodfellow","year":"2019","unstructured":"Goodfellow JA, Mackay GA. Autoimmune encephalitis. J R Coll Physicians Edinb. 2019;49:287\u201394.","journal-title":"J R Coll Physicians Edinb"},{"key":"2259_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157\u201365.","journal-title":"Lancet Neurol"},{"key":"2259_CR19","doi-asserted-by":"publisher","first-page":"117103","DOI":"10.1016\/j.jns.2020.117103","volume":"418","author":"V Oliveira","year":"2020","unstructured":"Oliveira V, Videira G, Samoes R, Carneiro P, Neves E, Santos E. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study. J Neurol Sci. 2020;418:117103.","journal-title":"J Neurol Sci"},{"key":"2259_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jamaneurol.2014.2956","volume":"72","author":"F Leypoldt","year":"2015","unstructured":"Leypoldt F, Hoftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol. 2015;72:180\u20136.","journal-title":"JAMA Neurol"},{"key":"2259_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1352458510389102","volume":"17","author":"M Khademi","year":"2011","unstructured":"Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17:335\u201343.","journal-title":"Mult Scler"},{"key":"2259_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0165-5728(02)00097-8","volume":"127","author":"TL Sorensen","year":"2002","unstructured":"Sorensen TL, Trebst C, Kivisakk P, Klaege KL, Majmudar A, Ravid R, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol. 2002;127:59\u201368.","journal-title":"J Neuroimmunol"},{"key":"2259_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ana.24783","volume":"80","author":"MR Pranzatelli","year":"2016","unstructured":"Pranzatelli MR. Elevated cerebrospinal fluid C-X-C motif chemokine 10: Commonalities in paraneoplastic neurological disorders. Ann Neurol. 2016;80:792\u20133.","journal-title":"Ann Neurol"},{"key":"2259_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cyto.2015.10.001","volume":"77","author":"K Kothur","year":"2016","unstructured":"Kothur K, Wienholt L, Brilot F, Dale RC. CSF cytokines\/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine. 2016;77:227\u201337.","journal-title":"Cytokine"},{"key":"2259_CR25","doi-asserted-by":"crossref","unstructured":"Wang Y, Miao A, Shi Y, Ge J, Wang L, Yu C, et al. Influencing electroclinical features and prognostic factors in patients with anti-NMDAR encephalitis: a cohort follow-up study in Chinese patients. Scientific Rep. 2020;10(1):10753.","DOI":"10.1038\/s41598-020-67485-6"},{"key":"2259_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/dmcn.14267","volume":"61","author":"M Nosadini","year":"2019","unstructured":"Nosadini M, Granata T, Matricardi S, Freri E, Ragona F, Papetti L, et al. Italian Working Group on Paediatric Anti Nm-DaRE: Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61:1101\u20137.","journal-title":"Dev Med Child Neurol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02259-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02259-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02259-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:09:01Z","timestamp":1638788941000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02259-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02259-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the 960 Hospital (201611). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. No disclosure relevant to the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}